Orthofix’s STIM onTrack 2.1 Mobile App Receives the US FDA’s Approval for Bone Growth Stimulators

 Orthofix’s STIM onTrack 2.1 Mobile App Receives the US FDA’s Approval for Bone Growth Stimulators

Orthofix’s STIM onTrack 2.1 Mobile App Receives the US FDA’s Approval for Bone Growth Stimulators

Shots:

  • The STIM onTrack technology is designed to work with Orthofix’s bone growth therapy devices, aid patients in adhering to their prescription and to improve their clinical outcomes
  • The news version of the mobile application captures the Patient Reported Outcome Measure (PROM) that enables patients to share their clinical responses in their home setting. The app is free and is supported by iOS and Android devices
  • The STIM onTrack 2.1 is designed to enhance treatment with the CervicalStim, SpinalStim and PhysioStimbone growth stimulators and is an upgrade version of original STIM onTrack mobile app that introduced in 2017

Click here ­to­ read full press release/ article | Ref: Orthofix | Image: Business wire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post